SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Nelson Mandela — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientNelson Mandela
Date of birth1918-07-18
IdentifiersMRN HR-ML021-SYN-TD; SSN (made up) 000-21-6718
Document date2001-07-14
AuthorThandiwe Mokoena, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month follow-up on androgen deprivation, ten days before radiotherapy. [S]

History of Present Illness

Mr. Mandela returns three months after his last visit, twelve weeks after his first leuprolide injection. He completed four weeks of bicalutamide. Hot flashes continue three or four times a week and are mild; his energy is a little lower in the afternoons, and he still walks every morning. His weight is up 1.2 kg since starting treatment. He has had no breast tenderness, chest pain, breathlessness, or leg swelling, and his mood and memory are unchanged. Fiducial markers were placed and the planning scans done a week ago, without complications. Radiotherapy starts in ten days. Urinary symptoms are unchanged. The audiology test after his wellness visit showed mild high-frequency hearing loss on the left, and he is thinking about a hearing aid. He takes vitamin D every day. [S]

ElementDetail
Androgen deprivationTwelve weeks on leuprolide; second injection given today
Side effectsMild hot flashes; slightly lower afternoon energy; weight up 1.2 kg
RadiotherapyFiducial markers placed and planning done; treatment starts in ten days
HearingMild high-frequency loss on the left on audiology

Review of Systems

SystemResultFinding
ConstitutionalPositiveSlightly lower afternoon energy; weight up 1.2 kg
EndocrinePositiveMild hot flashes three or four times a week; no breast tenderness
CardiovascularNegativeNo chest pain or leg swelling
GenitourinaryPositiveMild urinary frequency, unchanged; no blood in the urine
PsychiatricNegativeMood good; PHQ-2 score 1; no change in memory

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolideOne tablet once daily for four weeksOral route2001-04-14 to 2001-05-12completedS
Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, two doses twelve weeks apart (the second given at a primary care visit), about six months of androgen deprivation with radiotherapyOne injection every twelve weeks, two dosesIntramuscular route2001-04-21 to 2001-10-06completedS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2001-04-14activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2001-07-14Body height183cmS
2001-07-14Body weight81.6kgS
2001-07-14Body mass index (BMI) [Ratio]24.4kg/m2S
2001-07-14Systolic blood pressure134mm[Hg]S
2001-07-14Diastolic blood pressure78mm[Hg]S
2001-07-14Heart rate70/minS
2001-07-14Respiratory rate14/minS
2001-07-14Body temperature36.6CelS
2001-07-14Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2001-07-14Prostate specific Ag [Mass/volume] in Serum or Plasma0.9ng/mL<=4 ng/mLNormalS
2001-07-14Testosterone [Mass/volume] in Serum or Plasma18ng/dL264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivationLowS
2001-07-1425-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mL30-100 ng/mLNormalS
2001-07-14Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Physical Exam

Vital signs recorded on 2001-07-14; see the Vital Signs section. [S]

SystemFinding
GeneralWell
CardiovascularRegular rhythm; blood pressure 134/78 mm Hg; no ankle swelling
ChestNo gynecomastia
PerineumFiducial insertion sites healed

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate canceractiveconfirmed C61S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D).
Hormone-sensitive prostate canceractiveconfirmed Z19.1S — Synthetic status in the modern episode.
Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognitionactiveconfirmed Z79.899S — Synthetic androgen deprivation plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy.
History of pulmonary tuberculosis, treated, with no symptoms sinceresolvedconfirmed Z86.11S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryPSA on androgen deprivationEvery 3 to 6 monthsCompleted today0.9 ng/mL, down from 6.4
LaboratoryTestosteroneEvery 3 to 6 months on androgen deprivation (target below 50 ng/dL)Completed today18 ng/dL, castrate
Laboratory25-hydroxyvitamin DThree months after starting a supplementCompleted today34 ng/mL, up from 26
LaboratoryHemoglobin A1c or fasting glucose, and lipid panelBaseline and yearly on androgen deprivationUp to dateBaseline four months ago; next in eight months
ImagingBone density (DXA)Every 1 to 2 years on androgen deprivationUp to dateBaseline three months ago
ExaminationBlood pressure, weight, and cardiovascular assessmentEvery visit on androgen deprivationCompleted today134/78 mm Hg; weight 81.6 kg, up 1.2 kg since starting; no cardiac symptoms
Medication safetyHot flashes and fatigueEvery visit on androgen deprivationCompleted todayMild hot flashes three or four times a week; mild afternoon fatigue; no treatment wanted
SurveyDistress and depression screen (PHQ-2)At intervalsCompleted todayPHQ-2 score 1
SurveyCognitionPeriodically on androgen deprivationUp to dateMini-Cog 5 of 5 at the wellness visit five weeks ago; no change reported
SurveyUrinary symptomsBefore radiotherapy, then every follow-up visitCompleted todayMild frequency, unchanged from the baseline IPSS of 7
SurveyBowel function before radiotherapyBaseline before radiotherapy, then every visit after itDeferredNot asked today, a deviation from the protocol; the visit was taken up by the androgen deprivation results and the radiotherapy plan. To be checked at the next visit
Medication safetySecond leuprolide injectionEvery twelve weeks for two dosesCompleted todayGiven today in this clinic
Self-managementPhysical activity and calcium intakeEvery visitCompleted todayWalking every morning; resistance exercise twice a week; calcium from food

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part III: Principles of Radiation and Future Directions. J Urol 2022;208(1):26-33 (2022); Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026)

Follow-up: Radiotherapy from ten days' time, with weekly radiation oncology review. Primary care follow-up six weeks after radiotherapy ends, with PSA and testosterone. Next scheduled visit 2001-10-27: follow-up six weeks after radiotherapy: PSA, urinary and bowel effects, end of androgen deprivation, and the surveillance plan. [S]